




Annie Achee and Scott Okuno, MD

The NLMSF – SPAEN INTERNATIONAL LMS RESEARCH ROUNDTABLE

- Established 2019
- Roundtable Membership
 - Researchers
 - Clinicians
 - Worldwide
 - Focus on LMS



Why NLMSF Needed Organizational Structure



- The NLMSF- SPAEN INTERNATIONAL RESEARCH ROUNDTABLE
- The PATIENT-CAREGIVER ADVOCACY NETWORK ROUNDTABLE
- Annual Patient-Family LMS Education Symposia throughout the USA/Canada
- Education Webinar collaboration with other cancer organizations
- The Cancer Cell Line Project – patient drive tumor registry for Crisper Crispr / repurposed drug screening / global data access for Research
- NCI MyPart Network - patient natural history data collection partnership
- Connect with a Clinician Program for general Q & A
- Collaborative Partnerships with other organizations to enhance Patient – Family resource support
- Sarcoma Coalition – Steering Committee membership for collaboration with 20 other sarcoma organizations
- Research Advocacy Council – to collaborate with other sarcoma organizations to impact clinical trial patient participation and outcomes
- Three Foundation websites – to offer resource assistance throughout the diagnosis / treatment journey of patients and caregivers
- Weekly News Letters for clinical trial updates, research updates and wellbeing educational opportunities, well-being resource information

Executive Committee

- Meets monthly via conference call
- How to engage Roundtable members
- First Meeting of Roundtable
 - Host: Jon Trent, MD Sylvester Cancer Center
 - Course Director: Brian Van Tine, MD, PhD
 - Separate meeting from other meetings
 - One day meeting
- Set up process for RFP and review
- Manage 3 workgroups

Meeting: International Leiomyosarcoma Research Roundtable

- **Sylvester Comprehensive Cancer Center Miami, Florida September 14, 2019**
- **Meeting Focus:**
 - **Action papers to be generated from the meeting based on discussion topics**
 - **Better model references for LMS**
 - **Mechanism-based science**
 - **Identification of action markers for collaboration**
 - **Focusing on drug treatments for LMS**
 - **Data sharing – unpublished**

Agenda: Roundtable

September 14, 2019

8:00 am - Dr. Jonathan Trent, Dr. Scott Okuno - WELCOME

8:05 am - DISCUSSION SESSION 1 – OUR BASELINE UNDERSTANDING OF LMS
- Moderator, Dr. Jonathan Trent, MD

Presenters:	Topics:
Dr. Robin Jones, MD	History of LMS RR, PFR from SARC 02 Death of Olaratumab
Dr. Jonathan Trent, MD	Should ulms and Non-uLms be separated for research/clinical purposes
Dr. Silvia Stacchiotti, MD	Should uLms and Non-uLms be separated for research /clinical trial purposes

8:40 am Roundtable Open Discussion - lead by Dr. Jon Trent

9:00 am 15 Minute Break

9:15 am DISCUSSION SESSION 2 - GENOMICS - Moderator: Dr. Brian Van Tine, MD

Presenters:	Topics:
Dr. Alexander Lazar, MD	TGCA Talk on LMS
Dr. Matthew Hemming, MD	LMS Genomics and Modeling
Dr. Rebecca Gladdy, MD	Whole Genome Sequencing Defines LMS Evolution and Identifies Therapeutic Opportunities
Dr. Matt van de Rijn, MD	Circulating Tumor DNA and LMS and LM

10:05 am Roundtable Open Discussion - lead by Dr. Van Tine

10:15 am DISCUSSION SESSION 3 - TOOLS for STUDYING LMS
- Moderator, Dr. Scott Okuno, MD

Presenters:	Topics:
Dr. Scott Schuetze	Do our cell lines represent the disease Pro/Con and should we pursue organoid models
Dr. Patrick Schoffski	What PDX resources are available; what would be the most high yield in terms of model support
Dr. Ricardo Gonzalez	Discussion on LMS model Access expansion

11:00 am Roundtable Open Discussion - lead by Dr. Scott Okuno

5 Minute Break

11:15 am DISCUSSION SESSION 4 - BIOMARKER-DRIVEN TARGETS
- Moderator, Dr. Sujanna Movva

Presenters:	Topics:
Dr. Mahesh Seetharam, MD	mTor
Dr. Mathew Ingham, MD	BRCA
Dr. Robert SanFilippo, MD	ER/PR in STUMP

11:45 am Roundtable Open Discussion - lead by Dr. Sujanna Movva

NOON - 1 pm LUNCH

Hosted by: SARCOMA PATIENT EURO.NET and the NLMSF

1:00 pm DISCUSSION SESSION 5 - TKI's - Moderator, Dr. Breelyn Wilky, MD

Presenters:

Dr. Sebastian Bauer, MD
Dr. Richard Riedel, MD
Dr. Neeta Somaiah, MD

Topics:

TKI's in sarcoma and LMNS
What should we do next – Anlotinib and Tivozanib
GemTax vs Gempaz

1:45 pm Roundtable Open Discussion - lead by Dr. Breelyn Wilky

5 Minute Break

2:00 pm DISCUSSION SESSION 6 - IMMUNOTHERAPY TRIALS
- Moderator, Dr. Seth Pollack, MD

Presenters:

Dr. Margaret Von Mehren, MD
Dr. Seth Pollack, MD
Dr. Breelyn Wilky, MD
Dr. John Mullinax, MD

Topics:

SARC28 and Allaince
Ipi.nivo/Allaince/axitinib.pembro
DOX/Pembro
Axi/Pembro and Cabo Ipi/Nivo
Leveraging the Tumor Immune Infiltrate for Autologous Cellular Immunotherapy in LMS

3:30 pm Roundtable Open Discussion – lead by Dr. Seth Pollack

3:45 pm DISCUSSION SESSION 7 - TUMOR METABOLISM AND TP53
- Moderator, Dr. Brian Van Tine, MD

Presenters:

Dr. Brian Van Tine, MD

Topics:

ASS1, CB839+ADI-PEG10

Dr. Beverly Prudner, MD

Arginine starvation dramatically improving GE

Dr. Lisa Abliggen, Ph.D

TP53 and LMS

4:20 pm Roundtable Open Discussion – lead by Dr. Brian Van Tine

APPETIZERS /SNACKS PROVIDED

5:00 pm – 5:45 pm DISCUSSION SESSION 8 - CALL FOR COLLABORATIVE ACTION -
- Dr. Jonathan Trent

What specific “takeaways” from this meeting?

What collaborative projects would be important to pursue?

Collaborative actions identified / carried out (by whom)

Telecon meeting in 6 months to discuss progress made

Consensus on setting the 2020 date(s) for the Roundtable and a location

Post-Survey to complete and leave with Annie Achee

GRATITUDE TO ALL PARTICIPANTS, SPEAKERS, MODERATORS, EXECUTIVE COMMITTEE MEMBERS TO HELP COORDINATE TODAY’S MEETING.

THANK YOU TO DR. JONATHAN TRENT, HIRAM CORREA, Executive Assistant, AND MICHELLE HERNANDEZ, Executive Director, The SYLVESTER COMPREHENSIVE CANCER CENTER FACILITY and AV SUPPORT PERSONNEL FOR THE VALUABLE ASSISTANCE PROVIDED TODAY.

CONTRATULATIONS TO THE SYLVESTER COMPREHENSIVE CANCER CENTER FOR RESENT NCI DESIGNATION!

6:15 pm - COMPLIMENTARY SHUTTLE TO THE CONRAD HOTEL

7:00 pm - APPRECIATION / CELEBRATION DINNER – CONRAD HOTEL
Hosted by: The National Leiomyosarcoma Foundation

SPECIAL ACKNOWLEDGEMENT AND APPRECIATION EXTENDED TO THE SARCOMA PATIENT EURO.NET - Markus Wartenberg, Chair, Kathrin Schuster, Communications/Program Management, FOR COLLABORATIVE FUNDING WITH THE NLSMF FOR THE INAUGURAL INTERNATIONAL LMS RESEARCH ROUNDTABLE.

We have all gathered today - with the commitment of

“ACHIEVING MORE TOGETHER” - In the Quest for the Cure!

Outcome of the International LMS Research Roundtable: 3 Workgroups

- **PDX Models/LMS Cell Lines:**
 - Dr. Matthew Hemming Dana Farber Cancer Institute
- **Proteomics/Multiomics:**
 - Dr. Paul Huang, Institute of Cancer Research UK
- **Gynecologic Leiomyosarcoma/STUMP**
 - Dr. Roberta Sanfliippo, Aviano, IT

LMS PDX Models/Cell Lines: Hemming

- **Detailing the landscape of available leiomyosarcoma cell lines and patient-driven xenograft models**
- **Perform detailed sequencing to identify which are most relevant to the humans' disease**
- **Make efforts to collaboratively utilize these models to further leiomyosarcoma research**
- **GOAL: to perform transcriptional profiling of diverse leiomyosarcoma cell lines and draw comparisons between cell lines and primary tumors**
- **To do this, we are encouraging individual laboratories to prepare RNA in a standard fashion and submit samples for commercial sequencing at the same company**
- **Data will then be uploaded to a public repository, and analyzed collaboratively to identify cell lines with features that most consistently model leiomyosarcoma**

Proteomics/Multiomics: Huang

- Evaluate the current landscape of LMS Omics studies in the field
- Develop a roadmap for multi-modal data acquisition and integration in LMS (next generation sequencing, single cell technologies, proteomics, metabolomics, methylation, informatics, and AI)
- Evaluate potential for clinical utility of multi - omics in LMS molecular subtype classification, patient stratification and target discovery – real world and clinical trial specimens

Gynecologic LMS/STUMP: Sanfilippo

- **a) ESTABLISH A CLINICAL-RADIOLOGICAL TOOL FOR IMPROVING THE DIFFERENTIAL DIAGNOSIS OF LEIOMYOSARCOMAS (LMS) FROM LEIOMYOMAS (LM);**
- **b) ESTABLISH AN INTERNATIONAL CONSENSUS PROCESS REGARDING THE EXISTENCE OF LOW-GRADE UTERINE LMS.**
- Gather clinical and radiological consensus on ultrasound features that provide an indication for hysterectomy or for further radiological imaging as MRI
- Set up an observational prospective study on the use of MRI before surgery in patients that are candidates for hysterectomy
- Establish a prospective and retrospective observational study on STUMP with the aim to assess new pathologic criteria for uterine smooth muscle tumors or low malignancy grade or benign behavior in spite of pathologic aspects deviating from those typical of leiomyomas
- Organize a consensus event to refine the pathologic criteria on the differential diagnoses between STUMP, low-grade uterine smooth muscle tumors and typical high-grade leiomyosarcomas
- Establish a prospective study on the activity of hormonal treatment in recurrent uterine low grade leiomyosarcoma with a previous diagnosis of STUMP



- Annie and Scott Okuno support each other
- Delegation of responsibilities
- Next Meeting
 - Course Director: Breelyn Wilkey, MD
 - Location: Westin Hotel at Detroit Airport
 - Date: Saturday September 12, 2020

THANK YOU SARCOMA PATIENTS EURONET

FOR THE IMPACTFUL COLLABORATIVE SPIRIT OF SUPPORT
FOR THE INTERNATIONAL LMS RESEARCH ROUNDTABLE
THAT HOLDS PROMISE FOR CROSS-OVER RESEARCH TO
BENEFIT ANY SARCOMA SUBTYPE.

“What we can do today will affect what happens tomorrow”

